1 Evaluation of Viasure SARS-CoV-2 RT-qPCR kit (CerTest Biotec) using CDC FDA

2 EUA RT-qPCR kit as a gold standard.

- 3
- 4 Byron Freire-Paspuel¹, Patricio Vega-Mariño², Alberto Velez², Paulina Castillo², Marilyn Cruz²,

5 Franklin Perez³ and Miguel Angel Garcia-Bereguiain¹.

6

7 1. One Health Research Group. Universidad de Las Americas. Quito. Ecuador

8 2. Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos. Puerto

9 Ayora. Ecuador.

10 3. OneLab. Santa Elena. Ecuador.

11 #corresponding author: Miguel Angel Garcia-Bereguiain (magbereguiain@gmail.com).

12 Running Head: Evaluation of Viasure and CDC RT-qPCR kits for SARS-CoV-2.

13

Abstract. Background. Several RT-qPCR kits are available for SARS-CoV-2 diagnosis, some of 14 15 them with Emergency Use Authorization (EUA) by FDA, but most of them lacking of proper 16 evaluation studies due to covid19 emergency. Objective. We evaluated Viasure RT-gPCR kit (CerTest Biotec, Spain) for SARS-CoV-2 diagnosis using CDC FDA EUA kit as gold standard. 17 18 *Results*. Although we found the lack of RNA quality control probe as the main limitation for 19 Viasure kit, the sensitivity was up to 97.5% and specificity was 100%. Conclusions. Viasure RT-20 gPCR kit is a reliable tool for SARS-CoV-2 diagnosis but improvement of an alternative RT-gPCR 21 reaction for RNA extraction quality control as RNaseP is recommended.

23 Background.

24 Multiple in vitro RT-qPCR diagnosis kits are available on the market for the detection of SARS-25 CoV-2. Some of them have received emergency use authorization (EUA) from the U.S. Food & 26 Drug Administration (FDA), while for others only limited report validations made by manufacturers are available. The CDC designed 2019-nCoV CDC EUA kit (IDT, USA) is based on 27 28 N1 and N2 probes to detect SARS-CoV-2 that have received positive evaluation on recent 29 reports (1-4), and and RNase P as an RNA extraction guality control. Among the commercial kits 30 available in the market, Viasure SARS-CoV-2 RT-qPCR kit (CerTest Biotec; Spain) includes 31 "ORF1ab" and "N" probes for SARS-CoV-2 detection. However, no probe for RNA extraction 32 quality control is included but simply an "internal positive control" to guarantee that PCR 33 reaction performs well. Viasure SARS-CoV-2 kit is made in Spain, one of the countries leading 34 COVID19 cases and deaths worldwide, where it has been used for SARS-CoV-2 diagnosis. Also, it 35 was recently authorized for SARS-CoV2 diagnosis in Ecuador. However, it is not included on the 36 list of FDA EUA kits (5) and no evaluation study for Viasure SARS-CoV-2 RT-gPCR kit has been reported beyond the limited validation provided by manufacturer's manual including only two 37 38 SARS-CoV-2 positive samples (6).

39 **Objective.**

This study compared the performance in terms of sensitivity and specificity of Viasure SARS-CoV-2 and 2019-nCoV CDC EUA kits for SARS-CoV-2 RT-qPCR diagnosis from nasopharyngeal samples.

43 Study design.

104 clinical specimens (nasopharyngeal swabs collected on 0.5mL TE pH 8 buffer) were included
on this study, coming from individuals selected for SARS-CoV-2 surveillance at "LabGal"
("Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos") in
Galapagos Islands, starting on April 8th 2020. Also, four negative controls (TE pH 8 buffer) were
included as control for carryover contamination.

49 Results.

50 104 samples were tested for SARS-CoV-2 following an adapted version of the CDC protocol (1,2)51 using CFX96 BioRad instrument and PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) as an 52 alternate RNA extraction method; also, same RNA samples were tested using Viasure SARS-53 CoV-2 RT-gPCR kit following manufacturer's manual (6). For the 2019-nCoV CDC EUA kit, 81 54 samples tested positive and 23 samples tested negative (Tables 1 and 2). Considering only true positive samples for Viasure SARS-CoV-2 kit (amplification for both N and Orf1ab probes), 74 55 56 samples tested positive and 30 samples were negative; but if we consider as positive not only 57 true positives but also "presumptive positive" samples (only amplification of N probe), 79 samples tested positive and 25 were negative (Tables 1 and 2). The range of Ct values obtained 58 59 for 2019-nCoV CDC EUA were 22.61-38.58 and 24.02-41.7 for N1 and N2, respectively (Table 2). 60 The range of Ct values obtained for Viasure SARS-CoV-2 kit were 22.50-38.00 and 22.67-40.03 for N and Orf1ab, respectively (Table 2). The viral loads detailed on Table 2 were calculated 61 62 running a calibration curve with 2019-nCoV N positive control (IDT, USA), with a detection limit below 1 viral RNA copy. Viral loads (copies/uL) values for 2019-nCoV CDC EUA kit 63 64 positive/Viasure SARS-CoV-2 kit negative samples were 2 (sample ID 999c) and 3,8 (sample ID 65 1603); viral loads (copies/uL) values for 2019-nCoV CDC EUA kit positive/Viasure SARS-CoV-2 kit

66 presumptive positive samples were 4.900 (sample ID 448), 8,8 (sample ID 772), 4,36 (sample ID
67 1575), 2,96 (sample ID 1581) and 0,71 (sample ID 782) (See Table 2).

In summary, sensitivity for Viasure SARS-CoV-2 kit compared to 2019-nCoV CDC EUA was 91.4%
if we considered only true positives, but up to 97.5% if we considered also presumptive
positives as positive samples for SARS-CoV-2.

71 **Discussion**

72 Although the main limitation of our study is the sample size (104 specimens), our results support that Viasure SARS-CoV-2 RT-qPCR kit had a great performance in terms on sensitivity 73 74 and specificity compared to 2019-nCoV CDC EUA, with values up to 97.5 and 100%, 75 respectively. According to Viasure SARS-CoV-2 kit manufacturer's manual, when a sample only 76 yields amplification for N probe but Orf1ab is negative, the result should be SARS-CoV-2 77 negative and a possible infection by other coronavirus must be considered (6). However, on our 78 hands, all the Viasure SARS-CoV-2 N positive/Orf1ab negative were confirmed as SARS-CoV-2 79 positive by CDC protocol (1,2), and thus we referred to this samples as presumptive positive. 80 Moreover, Viasure SARS-CoV-2 kit manufacturer's manual set a limit of detection of 10 viral 81 copies/uL for its product. With the only exception of sample 448 (viral load of 4.300 copies/uL), 82 all the Viasure SARS-CoV-2 kit presumptive positive and negative samples yield viral loads 83 below 10 copies/uL, confirming the expected limit of detection of the kit.

The lack of any probe for RNA extraction quality control like RNaseP is a limitation to be considered when using Viasure SARS-CoV-2 kit. Although in our experience, samples failing to yield any RNA after extraction are below 1%, an extra RT-qPCR reaction for a RNA extraction quality control probe would be recommended for laboratories starting SARS-CoV-2 diagnosis.

88 On the other hand, Viasure SARS-CoV-2 kit is provided on precast format of 8 tubes strips 89 containing a mix of enzymes, primers, buffer and nucleotides in stabilized format, so only 90 rehydratation buffer and RNA samples have to be added. This format is a great advantage in 91 terms of time saving and reduction on pippeting mistakes. Also, the manufacturer provided us upon request the concentration of the positive control included on Viasure SARS-CoV-2 kit 92 93 (10.000 copies/uL). That means viral loads can be easy calculated without need of purchase any 94 extra positive control, despite the manufacturer's manual does not include instruction for viral 95 load calculation (6). 96 Considering the worldwide high demand of reagents for SARS-CoV RT-qPCR diagnosis, supplies 97 shortage is a fact, actually affecting harder to developing countries like Ecuador. Under this 98 scenario, validation studies are helpful to guarantee the quality of the supplies in the market for 99 every country in the world, as not necessary all the SARS-CoV-2 RT-qPCR kits show the 100 performance indicated by manufacturer (7). 101 **Ethical considerations** All samples have been submitted for routine patient care and diagnostics at Galapagos Islands. 102

103 This study was authorized by "Comité de Operaciones Especiales Regional de Galápagos" that is 104 leading board for Covid19 surveillance in Galapagos Islands. All data used in the current study 105 was anonymized prior to being obtained by the authors.

106 **Funding**.

107 None.

108 Authorship contribution statement.

- 109 All authors contributed to study conceptualization, experimental procedures and revision and
- 110 approval of final version of the manuscript.
- 111 Byron Freire-Paspuel and Miguel Angel García Bereguiain analyzed the data and wrote the
- 112 manuscript.
- **Declaration of Competing Interest.**
- 114 All authors have no conflict of interest to declare.

115 Acknowledgements.

We thank the medical personnel from "Ministerio de Salud Pública" at Galapagos Islands and the staff from the "Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos" for their support. We also thank Dr. Ronald Cedeño from OPS/WHO for his work during Covid 19 surveillance in Galapagos Islands. We specially thank Gabriel Iturralde, Oscar Espinosa and Dr Tannya Lozada from "Dirección General de Investigación de la Universidad de Las Américas", and also the authorities from Universidad de Las Américas, for logistic support to make SARS-CoV-2 diagnosis possible in Galapagos Islands.

123 References.

124 1. Xiaoyan Lu, Lijuan Wang, Senthilkumar K. Sakthivel, Brett Whitaker, Janna Murray, Shifaq

125 Kamili, Brian Lynch, Lakshmi Malapati, Stephen A. Burke, Jennifer Harcourt, Azaibi Tamin,

- 126 Natalie J. Thornburg, Julie M. Villanueva and Stephen Lindstrom. US CDC Real-Time Reverse
- 127 Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2.

128 *Emerging Infectious Diseases*. 2020. Volume 26:8.

129 2. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for

130 Coronavirus Disease 2019 (COVID-19). Center for Diseases Control and Prevention, USA.

- 131 https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html (last
 132 access 04/20/20).
- 133 3. Daniel D. Rhoads, Sree S. Cherian, Katharine Roman, Lisa M. Stempak, Christine L.
- 134 Schmotzer, Navid Sadri. Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA
- 135 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from
- individuals diagnosed with COVID-19. Accepted Manuscript Posted Online 17 April 2020.
- 137 *J. Clin. Microbiol.* doi:10.1128/JCM.00760-20.
- 138 4. Arun K. Nallaa, Amanda M. Castob, Meei-Li W. Huanga, Garrett A. Perchettia, Reigran
- 139 Sampoleoa, Lasata Shresthaa, Yulun Weia, Haiying Zhua, Keith R. Jeromea, Alexander L.
- 140 Greningera. Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different
- 141 Primer/Probe Sets and One Assay Kit. JCM Accepted Manuscript Posted Online 8 April 2020. J.
- 142 *Clin. Microbiol.* doi:10.1128/JCM.00557-20.
- 143 5. <u>https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-</u>
- 144 <u>use-authorizations</u> (last accession date 06/14/2020).
- 145 6. https://www.certest.es/wp-content/uploads/2020/03/IU-NCO212enes0420-rev.01.pdf.
- 146 7. Byron Freire-Paspuel, Patricio Vega-Mariño, Alberto Velez, Paulina Castillo, Marilyn Cruz,
- 147 Miguel Angel Garcia-Bereguiain. Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR Detection
- 148 of SARS-CoV-2 From Nasopharyngeal Samples Using CDC FDA EUA qPCR Kit as a Gold Standard:
- 149 An Example of the Need of Validation Studies. *J Clin Virol*. 2020 May 22;128:104454. doi:
- 150 10.1016/j.jcv.2020.104454.
- 151

152

Table 1. Performance of Viasure SARS-CoV-2 compared to 2019-nCoV CDC EUA for RT-qPCR SARS-CoV-2 diagnosis (% values: sensitivity). Presumptive positive samples only amplified for N probe with Viasure SARS-CoV-2 kit.

	Viasure Positive	Viasure positive + presumptive positive	Viasure Negative	Total	
CDC Positive	74 (91.4 %)	79 (97.5%)	2	81	
CDC Negative	0	0	23	23	
Total	74	79	25	104	

Table 2. Ct Values for nCoV-2019 CDC EUA kit and Viasure SARS-CoV-2 RT-qPCR kits for all the samples included on the study. RNaseP is the
RNA extraction quality control for nCoV-2019 CDC EUA kit. IPC is the internal positive control for Viasure SARS-CoV-2 kit. Samples in bold
were positive for nCoV-2019 CD EUA kit but either negative or presuntive positive for Viasure SARS-CoV-2 kit (N/A means not amplified).

sample number	sample ID	N1 Ct Value	N2 Ct Value	RNaseP Ct Value	Viral Load (copies/µL)	CDC Result	ORF1a Ct Value	N Ct Value	IPC Ct Value	VIASURE Result
1	943B	32,41	36,46	31,43	68	Positive	30,15	30,73	19,39	Positive
2	958	27,45	32,8	28,24	6.900	Positive	26,75	27,49	19,66	Positive
3	968	27,3	31,96	33,02	8.000	Positive	25,09	25,71	19,6	Positive
4	977	30,4	35,31	29,14	450	Positive	29,71	30,14	19,48	Positive
5	986	32,31	37,12	36,02	92	Positive	28,59	29,24	18,91	Positive
6	992	26,06	30,08	30,46	17.000	Positive	26,19	26,33	19,16	Positive
7	1008	26,86	32,46	35,99	10.000	Positive	23,73	24,46	18,78	Positive
8	1009	31,9	35	31,11	170	Positive	29	30,02	18,82	Positive
9	999	29,86	34,04	35,83	900	Positive	26,39	27,26	18,92	Positive
10	448	28,38	29,95	29,04	4.900	Positive	N/A	28,1	18,14	Presumptive Positive
11	449	25,93	27,99	28,26	25.000	Positive	25,84	25,93	18,74	Positive
12	668	25,15	26,59	31,26	33.000	Positive	23,53	25,31	19,09	Positive
13	943c	30,34	33,23	25,32	700	Positive	30,02	30,26	19,8	Positive
14	944c	31,75	34,4	21,73	240	Positive	30,52	31,35	20,05	Positive
15	945c	32,24	34,87	23,17	160	Positive	31,25	31,27	19,99	Positive
16	946c	37,53	39,62	25,27	2,8	Positive	39,82	35,41	19,68	Positive
17	949c	27,31	29,82	25,43	7.200	Positive	27,86	28,18	20,1	Positive
18	950c	23,34	25,16	22,69	150.000	Positive	22,67	22,56	19,94	Positive
19	955c	35,33	37,47	26,37	15	Positive	32,54	30,2	19,69	Positive
20	963c	30,42	32,37	29,23	660	Positive	30,35	30,79	19,61	Positive
21	965c	31,62	33,76	27,32	260	Positive	29,44	27,66	18,92	Positive
22	966c	25,53	28,02	26,11	28.000	Positive	25,23	26,05	19,66	Positive
23	967c	26,05	27,94	26,12	19.000	Positive	26,12	26,42	19,68	Positive
24	968c	23,02	24,8	25,04	190.000	Positive	23,35	23,26	19,84	Positive

25	970c	36,01	40,09	24,87	9	Positive	38,63	35,83	20,06	Positive
26	983c	27,01	28,19	29,27	3.100	Positive	26,76	27,6	19,42	Positive
27	985c	22,61	24,02	26,52	81.000	Positive	25,08	25,72	19,54	Positive
28	986c	33,9	37,34	26,26	19	Positive	32,84	30,13	18,86	Positive
29	988c	34,76	36,8	32,08	9,9	Positive	34,3	34,79	19,06	Positive
30	989c	35,81	37,05	29,83	4,5	Positive	35,6	36,24	21,06	Positive
31	991c	28,8	29,98	28,39	830	Positive	28,69	28,72	18,92	Positive
32	993c	36,1	40,01	28,67	3,7	Positive	39,82	36,6	19,01	Positive
33	997c	28,27	29,82	30,58	1.200	Positive	28,43	29,11	19,57	Positive
34	999c	36,94	41,7	36,37	2,0	Positive	N/A	N/A	17,69	Negative
35	1008c	28,11	29,54	28,98	1.400	Positive	29,08	29,46	19,3	Positive
36	1009c	30,64	32,08	30,05	210	Positive	30,99	31,2	19,28	Positive
37	1102	34,05	34,43	27,53	32	Positive	38,11	34,04	19,58	Positive
38	772	34,42	35,2	28,16	8,8	Positive	N/A	35,14	19,47	Presumptive Positive
39	1289	33,5	34,71	27,09	15,8	Positive	34,48	34,69	19,64	Positive
40	1290	31	32,15	23,68	157	Positive	31,05	32,05	19,04	Positive
41	1292	32,54	33,39	26,03	38,3	Positive	32,88	34,41	19,33	Positive
42	1284	33,54	34,22	24,94	15,2	Positive	33,77	34,27	20,03	Positive
43	1286	35	35,87	26,18	3,95	Positive	35,11	36,18	20,72	Positive
44	1293	27,57	28,06	25,65	3.730	Positive	27,46	28,39	20,41	Positive
45	1295	29,51	29,98	26,8	624	Positive	28,48	30,03	20,06	Positive
46	1296	29,15	29,47	25,88	869	Positive	28,82	29,94	20,11	Positive
47	1297	32,18	32,81	27,07	53,2	Positive	32,62	33,01	20,42	Positive
48	1382	N/A	N/A	30,76	N/A	Negative	N/A	N/A	20,14	Negative
49	1383	N/A	N/A	30,47	N/A	Negative	N/A	N/A	20,05	Negative
50	1384	N/A	N/A	26,97	N/A	Negative	N/A	N/A	20,39	Negative
51	1385	N/A	N/A	24,36	N/A	Negative	N/A	N/A	20,2	Negative
52	1386	N/A	N/A	28,68	N/A	Negative	N/A	N/A	20,17	Negative
53	1391	N/A	N/A	24,84	N/A	Negative	N/A	N/A	19,48	Negative
54	1392	N/A	N/A	26,99	N/A	Negative	N/A	N/A	20,05	Negative
55	1409	N/A	N/A	28,09	N/A	Negative	N/A	N/A	19,92	Negative
56	1411	N/A	N/A	29,92	N/A	Negative	N/A	N/A	20,05	Negative

57	1412	N/A	N/A	27,49	N/A	Negative	N/A	N/A	20,33	Negative
58	1413	N/A	N/A	29,25	N/A	Negative	N/A	N/A	20,26	Negative
59	1414	N/A	N/A	28,59	N/A	Negative	N/A	N/A	20,02	Negative
60	1415	N/A	N/A	28,14	N/A	Negative	N/A	N/A	19,81	Negative
61	1416	N/A	N/A	27,24	N/A	Negative	N/A	N/A	20,68	Negative
62	1550	34,41	33,99	30,16	12,5	Positive	33,55	34,48	20,19	Positive
63	1556	36,16	38,06	29,75	2,77	Positive	36,19	35,76	20,5	Positive
64	1564	32,86	33,51	31,34	20,9	Positive	32,96	33,08	20,07	Positive
65	1575	34,86	37,11	28,18	4,36	Positive	N/A	36,91	20,06	Presumptive Positive
66	1581	35,35	36,02	27,22	2,96	Positive	N/A	37,83	20,81	Presumptive Positive
67	1582	33,23	34,24	27,05	15,6	Positive	34	33,52	20,13	Positive
68	1586	38,58	38,21	29,01	49,1	Positive	37,77	36,77	19,94	Positive
69	1589	32,08	33,21	27,14	152	Positive	33,7	33,28	20,08	Positive
70	1597	34,97	37,41	32,01	27,1	Positive	40,03	36,01	19,99	Positive
71	1603	36,41	40,02	24,74	3,83	Positive	N/A	N/A	21,18	Negative
72	315	34,64	39,15	26,39	17,3	Positive	35,08	35,19	21,14	Positive
73	347	29,24	30,84	30,06	488	Positive	29,08	30,46	20,89	Positive
74	351	34,1	36,68	31,47	15,1	Positive	33,91	34,16	21,06	Positive
75	357	38,05	39,64	33,8	3,34	Positive	35,07	35,04	21,13	Positive
76	365	31	33,71	28,74	139	Positive	31,04	31,39	20,98	Positive
77	372	36,27	38,44	28,63	1,23E+00	Positive	38,62	36,24	20,04	Positive
78	782	38,29	40.01	26,58	0,71	Positive	N/A	39,16	20,93	Presumptive Positive
79	783	32,76	35,79	31,05	86,3	Positive	32,45	32,92	21,02	Positive
80	856	33,17	33,35	23,06	54,8	Positive	33,81	33,5	19,92	Positive
81	878	35,03	41,35	30,933317	12	Positive	33,65	34,25	20,81	Positive
82	945	35,05	40,11	30,8	5,74	Positive	34,37	34,48	21,03	Positive
83	946	35,8	40,02	30,2	2,86	Positive	33,3	34,52	20,83	Positive
84	949	34,95	40,2	36,68	6,32	Positive	32,15	32,25	20,89	Positive
85	952	34,65	39,77	35,53	8,35	Positive	32,36	33,39	21,1	Positive
86	952c	38,58	40,06	27,74	1,24	Positive	38,17	38	20,8	Positive
87	955	34,6	40,02	33	8,79	Positive	32,77	33,01	21,08	Positive

88	963	32,66	38,06	34,64	53,4	Positive	29,96	29,83	20,81	Positive
89	965	26,7	32,92	35,75	13.900	Positive	23,24	24,35	20,74	Positive
90	966	32,76	37,49	27,44	48,8	Positive	31,08	32,23	20,93	Positive
91	967	31,34	36,15	32,29	184	Positive	27,62	29,05	20,96	Positive
92	988	35,59	39,27	34,22	6,01	Positive	30,11	31,29	20,04	Positive
93	991	33,51	38,74	38,2	33,7	Positive	30,96	31,25	20,08	Positive
94	997	33,11	38,4	38,3	47	Positive	27,8	27,16	20,74	Positive
95	527	35,42	34,25	35,18	10,3	Positive	38,78	36,52	20,52	Positive
96	1353	N/A	N/A	29,47	N/A	Negative	N/A	N/A	19,21	Negative
97	1355	N/A	N/A	29,76	N/A	Negative	N/A	N/A	20,03	Negative
98	1356	N/A	N/A	29,66	N/A	Negative	N/A	N/A	19,59	Negative
99	1357	N/A	N/A	27,51	N/A	Negative	N/A	N/A	19,03	Negative
100	1358	N/A	N/A	27,71	N/A	Negative	N/A	N/A	19,19	Negative
101	1361	N/A	N/A	28,71	N/A	Negative	N/A	N/A	20,24	Negative
102	1362	N/A	N/A	28,73	N/A	Negative	N/A	N/A	20,35	Negative
103	1363	N/A	N/A	30,24	N/A	Negative	N/A	N/A	19,23	Negative
104	1364	N/A	N/A	30,04	N/A	Negative	N/A	N/A	19,49	Negative